August 2026 Research Update

Across these studies, genetic testing for congenital adrenal hyperplasia (CAH) is moving toward sequencing-based workflows that can confirm CYP21A2 gene changes more quickly and at lower or comparable cost than older step-by-step approaches. Short-read and long-read sequencing both showed high agreement with traditional confirmation methods, while also highlighting remaining gaps, especially around complex rearrangements and exact copy number. [1] [2] [3]

Two clinic-focused studies reported that targeted short-read next-generation sequencing for CYP21A2 can match Sanger sequencing closely for calling sequence variants. In one validation study, one short-read analysis pipeline detected all variants seen by Sanger in the pilot phase, while another missed a specific disease-causing change, showing that software choice can matter. [1] [3]

Copy-number changes (such as deletions or duplications) remained a key technical challenge. One short-read pipeline could not detect whole-gene deletions or complex rearrangements and still relied on an added test for copy number, while another targeted short-read approach reported it could detect copy-number alterations and some chimeric rearrangements, with deletions confirmed by an additional method. [1] [3]

In a large newborn screening experience in Fujian, China, adding long-read sequencing to the usual hormone-based screening identified babies with two disease-causing CYP21A2 changes, including some with normal initial hormone screening results in a prospective cohort. This long-read approach also reported faster end-to-end turnaround and fewer unnecessary recalls compared with confirmation pathways that use multiple separate tests. [2]

For patients and families, these studies mainly matter as background on how CAH confirmation and carrier testing may be performed in different hospitals and newborn screening programs. The direction across studies suggests sequencing can provide accurate answers more quickly, but some results (especially complex rearrangements or exact copy number) may still require an extra confirmation step depending on the laboratory. What remains uncertain is how well each approach performs across many centers and populations, and which exact sequencing workflow will become standard in routine care. [1] [2] [3]

These papers focused on two practical parts of detection: how quickly newborn screening reaches babies and families, and how hormone test levels line up with genetic confirmation in older children. Overall, they show that system factors (like when the blood spot is collected) can create delays for certain groups, and that hormone thresholds can be anchored to CYP21A2 genotyping to improve how well testing separates nonclassic CAH from similar-looking conditions. [4] [5] [6]

In a multicenter Korean pediatric CAH cohort, newborn screening was linked to earlier diagnosis for salt-wasting 21-hydroxylase deficiency, with fewer salt-wasting-related symptoms at the time of diagnosis after screening was introduced. The study also reported that genotype patterns helped predict classic versus nonclassic presentations, especially when variants were expected to leave little or no enzyme activity. [6]

In Istanbul, Turkey, the first year of a CAH newborn screening program showed similar screening performance between local newborns and immigrants or refugees, but sample collection happened later in immigrant or refugee babies. Transfer and approval times were similar, pointing to the earliest step (getting the sample collected) as the main source of delay in that setting. [4]

In children evaluated for premature pubarche (early pubic hair), a diagnostic accuracy study used CYP21A2 genotyping as the reference to identify 17-hydroxyprogesterone (17OHP) hormone levels that best matched nonclassic 21-hydroxylase deficiency. It reported one basal 17OHP cutoff with a balance of sensitivity and specificity, a higher cutoff with very high specificity, and a post-stimulation 17OHP cutoff that matched the genetic diagnosis perfectly in that dataset. [5]

For families, these studies emphasize that screening results are influenced both by biology (hormone levels and genotype) and by program logistics (when a newborn sample is collected). The hormone-threshold work may help clinicians interpret testing in children with early signs of androgen effects, but the exact cutoffs may differ by lab method and population, so they are not automatically transferable everywhere. The newborn screening studies suggest earlier detection can reduce how often babies show up already very ill with salt-wasting symptoms, while also showing that access barriers (like delayed sampling in migrant groups) can affect timeliness. [4] [5] [6]

Across these papers, the main pattern is that congenital adrenal hyperplasia (CAH) can be overlooked when symptoms are attributed to more common situations (like adrenal incidentalomas or polycystic ovary syndrome), and CAH-like lab results can sometimes occur for other reasons. The evidence here comes from two case reports (single patients or a pair of patients) plus one cross-sectional study, so it highlights real-world diagnostic challenges but cannot define how often they occur in every setting. Overall, the studies point to the value of careful hormone testing and, when available, genetic confirmation to sort out CAH from look-alike conditions. [7] [8] [9]

In two adult men, adrenal masses found incidentally on imaging led to the diagnosis of previously unrecognized classic 21-hydroxylase deficiency. Both had clearly elevated 17-hydroxyprogesterone and were found to carry disease-causing CYP21A2 gene variants, supporting the idea that long-term hormone signaling that stimulates the adrenal glands can contribute to adrenal nodules over time. [7]

In one late preterm newborn girl, early low cortisol along with elevated 17-hydroxyprogesterone and androgens looked like CAH at first, but the picture was temporary and later testing supported a different diagnosis: Beckwith-Wiedemann syndrome due to IC2 hypomethylation. Imaging did not show enlarged adrenal glands or tumors, and the clitoral enlargement resolved by six months, emphasizing that not every CAH-like early hormone pattern is due to CAH. [8]

In a clinic-based study of 120 South Indian women diagnosed with polycystic ovary syndrome (PCOS), hormone stimulation testing with detailed steroid measurement identified CAH in 3 women (2.5%): two with classic 21-hydroxylase deficiency and one with 11-beta-hydroxylase deficiency. All three had severe signs of high androgens (including severe hirsutism and clitoromegaly), and genetic testing found variants in CYP21A2 or CYP11B1 that matched the hormone results; no non-classic CAH cases were found in this group. [9]

For patients and caregivers, this set of studies is mainly about understanding why CAH is sometimes recognized late or confused with other conditions. It suggests that, in some adults, adrenal nodules can be a clue to previously unrecognized CAH, and that in newborns, rare growth syndromes can temporarily resemble CAH on early hormone tests. It also shows that in a PCOS clinic population, a small minority had CAH detected only after more detailed testing, but the exact rate may differ by country, referral patterns, and which tests are available.

Across these papers, hormone management in congenital adrenal hyperplasia (CAH) is shown as a balancing act that changes with age and situation: reducing excess androgens in adolescents and young adults, and avoiding mineralocorticoid over-replacement in early childhood. Evidence is mainly from moderate-strength observational data and guideline recommendations, so many details still rely on expert consensus. [10] [11] [12]

In a prospective observational study of 17 young women with classic 21-hydroxylase deficiency who started combined oral contraceptives, several androgen-related blood markers decreased and urine androgen metabolites fell over follow-up. The study also reported higher cortisol levels after starting the contraceptive, and 8 participants reduced their hydrocortisone dose between visits, alongside the biochemical shifts toward lower androgen levels. [10]

In a retrospective cohort of 28 children followed from birth to age 3, fludrocortisone dosing was highest around 3 months and then leveled off after about 1 year. Higher renin levels tracked with lower sodium and higher potassium, while suppressed renin was linked to the highest predicted probability of high blood pressure; renin levels did not appear to change linear growth in this dataset. [11]

An updated set of author clarifications to Russian pediatric CAH guidelines reinforced that treatment plans typically include glucocorticoid and, for salt-wasting forms, mineralocorticoid replacement with ongoing follow-up that considers age, growth, and bone development. The guideline notes uneven evidence strength across recommendations, cautions about growth effects with long-acting glucocorticoids, and states that prenatal dexamethasone therapy is not recommended due to risks. [12]

For patients and caregivers, these papers add context for why monitoring in CAH often includes both hormone markers (to understand androgen control) and measures related to salt balance and blood pressure (to watch for mineralocorticoid over- or under-replacement), especially in infancy and early childhood. The contraceptive study mainly informs how hormone patterns may shift in young women using combined oral contraceptives, but it does not establish what changes are best for symptoms or long-term outcomes. The guideline content is useful background for understanding what pediatric care commonly tracks, while also highlighting that some recommendations are based more on expert consensus than on high-level trial data. [10] [11] [12]

These reports describe a small number of individual patients where fertility problems were the clue to less common causes of congenital adrenal hyperplasia (CAH), including enzyme-related conditions that can raise progesterone levels or create ovarian adrenal rest tumors. Overall, they suggest that detailed hormone testing and, in some cases, genetic testing can help explain otherwise unexplained infertility, but outcomes varied from live birth to miscarriage. The evidence here is limited because all data come from case reports rather than larger studies. [13] [14] [15]

In two women with infertility and persistently high progesterone, testing pointed to non-classic P450 oxidoreductase deficiency (NC-PORD), supported by POR gene variants and hormone responses on stimulation testing. After dexamethasone suppression, progesterone dropped to very low levels and the uterine lining measurements improved, allowing embryo transfer with assisted reproduction; one pregnancy ended in miscarriage and another was ongoing at the time of the report. The authors noted limits in genetic testing that meant they could not fully rule out other related CAH conditions in these cases. [13]

One 28-year-old woman with partial 17 alpha-hydroxylase/17,20-lyase deficiency had infertility and an unusual hormone profile (high progesterone and 17-hydroxyprogesterone with low androgens) linked to compound CYP17A1 mutations. After prednisone treatment, she conceived through in vitro fertilization with frozen embryo transfer and delivered a healthy baby. This single-patient report highlights that partial forms can look different from classic descriptions and still be relevant in fertility settings. [14]

Another report described a woman in her 20s with CAH due to 11 beta-hydroxylase deficiency who had bilateral ovarian adrenal rest tumors and later developed autoimmune Addison's disease with ovarian failure. She conceived spontaneously twice and her ovarian tumors completely regressed under glucocorticoid therapy, but years later she experienced an Addisonian crisis and developed mineralocorticoid deficiency. Because this is one patient, it mainly illustrates that multiple adrenal and ovarian conditions can rarely occur together and affect reproductive function over time. [15]

For patients and caregivers, this set of case reports is most useful as background on why fertility challenges in CAH can sometimes involve less common enzyme conditions or ovarian adrenal rest tumors, and why hormone patterns like persistently high progesterone may prompt deeper evaluation in some infertility clinics. It also shows that pregnancy outcomes can differ widely even when hormone levels improve, and that autoimmune adrenal disease can complicate reproductive health in rare situations. What remains uncertain is how often these scenarios occur, which tests best identify them, and how consistently different management approaches lead to live birth, since larger studies were not included here.

Across these papers, the main message is that careful mapping of internal anatomy can change how differences of sex development (DSD) are understood and described before and during surgery. Two studies suggest that what is visible on scans or laparoscopy usually matches operative anatomy, but small structures can sometimes be missed without more detailed testing. [16] [17]

In a retrospective series of 21 girls with virilized genitalia due to congenital adrenal hyperplasia who had feminizing genitoplasty, most had a low vaginal insertion when classified using a pelvic bone landmark (the I-point) on a side-view contrast study. The imaging-based classification agreed with what surgeons found during the operation in this group, supporting its potential use for preoperative planning. [16]

A case report of a 15-year-old with 46,XY and genetically confirmed 17 alpha-hydroxylase/17,20-lyase deficiency found no visible Mullerian structures during laparoscopy, yet microscopic Mullerian duct remnants were seen on tissue examination after gonad removal. Genetic testing did not identify a clear explanation in certain anti-Mullerian hormone pathway genes, showing that some anatomy differences may be subtle and not explained by targeted genetics in a single patient. [17]

For families dealing with DSD-related genital or internal anatomy questions, these reports mainly add background about how anatomy can be assessed and described around surgery. The classification study relates specifically to congenital adrenal hyperplasia and suggests one imaging approach may line up well with operative anatomy in a small group, while the single-patient report highlights that tiny internal remnants may only be found with microscopic examination and may not be predictable from targeted gene testing.

Together, these studies describe how DSD care often spans prenatal assessment, genetic testing, postnatal evaluation, and coordinated specialty follow-up. They also show that genetic testing does not provide an answer for everyone and that some prenatal concerns do not turn into confirmed DSD after birth. [18] [19]

In a retrospective review of 255 prenatal referrals for suspected DSD, genetic testing provided a diagnosis in 22% of the cases that had sufficient testing data reported (21 of 94). Among fetuses with postnatal information, 22% were ultimately considered false positive referrals, and the diagnosed conditions included both chromosome-related findings and single-gene conditions such as congenital adrenal hyperplasia and androgen insensitivity. [18]

A separate 10-year pediatric cohort from Duhok, Iraq reported that congenital adrenal hyperplasia was the most common DSD diagnosis in their clinic population (48.1% of 52 children). The authors described using karyotype and hormone testing (and endoscopy when needed) within a multidisciplinary approach, and they reported improved surgical outcomes, although specific outcome numbers were not provided in the summary. [19]

This theme may be most relevant for families navigating DSD evaluation either during pregnancy or in childhood. The prenatal study helps set expectations that genetic testing can sometimes identify a specific cause but often does not, and that some prenatal concerns may not be confirmed after birth. The pediatric clinic report reinforces that congenital adrenal hyperplasia is a common diagnosis in DSD care and that evaluation often involves coordinated medical, genetic, and surgical assessments, but the details of which approaches work best remain uncertain from these summaries.

Across these papers, the overall message is that family experiences in congenital adrenal hyperplasia (CAH) and related conditions can be captured and tracked using structured tools and programs, but the evidence is still developing. A short, multidisciplinary training program was linked to stable or improved quality of life for many participants, while a translated survey tool showed acceptable overall reliability but needs more validation before broad use. [20] [21]

In a multi-center German study of a two-day Empower-DSD training for children, teens, young adults with differences of sex development (including CAH) and their parents, health-related quality of life was stable or improved for a majority over 3 to 6 months. By 6 months, relevant improvement was reported by 35% of children, 25% of adolescents, and 32% of young adults, with similar stability or improvement reported for over 66% of children and parents overall. Qualitative feedback suggested that meeting peers and having psychological support helped some participants feel more confident and informed, though some also experienced the sessions as emotionally stressful or upsetting. [20]

In Indonesia, researchers translated and tested an Indonesian version of the Parent's Perception of Uncertainty Scale in parents of children with CAH, type 1 diabetes, or Down syndrome. The final version had 24 items in three areas (ambiguity, unpredictability, and lack of clarity) with acceptable overall reliability (Cronbach's alpha 0.839), but individual subscales performed only modestly and several items were removed due to weaker performance. The authors emphasized that the scale shows potential for research on parental uncertainty, but needs refinement and additional validation, especially in more uniform groups. [21]

For families living with CAH, these studies mainly add background evidence about ways researchers try to measure and support day-to-day well-being. The training-program results suggest that structured education plus peer connection may help some families feel better over the following months, but because there was no comparison group, it is not clear how much of the change was due to the program itself. The uncertainty-scale work matters most for future research, since it may eventually help teams track how unclear or unpredictable the condition feels to parents, but the Indonesian version still needs further testing before it can be considered well-established.

Across these papers, complications outside the adrenal glands involved the lungs and testes, and some issues were not obvious until tested or until a major stress event occurred. The evidence is early: one small case-control study and one single-patient report, so the results describe possibilities rather than what happens to everyone with congenital adrenal hyperplasia (CAH). [22] [23]

In a small case-control study of 27 children with CAH and 27 matched healthy children, impulse oscillometry (a breathing test that can pick up small-airway changes) showed higher measures of peripheral and overall airway resistance in the CAH group. Several children with CAH had abnormal scores in these small-airway measures even though standard large-airway measures did not differ, suggesting possible subclinical small-airway dysfunction. [22]

A separate case report described one 22-year-old man with untreated CAH who had both testes removed for testicular adrenal rest tumors (TARTs) and then developed a severe adrenal crisis 18 days later. He improved after starting steroid hormone replacement, and the authors highlighted that TARTs can be a sentinel (warning) sign of CAH when someone presents with bilateral testicular masses. [23]

For patients and caregivers, these studies add context that CAH can involve other body systems in ways that may not be obvious day to day. The lung study is mainly background research that may help explain or detect subtle breathing changes, but it does not show whether these test results lead to symptoms or long-term lung problems. The single-patient TART report is most relevant as a reminder that testicular masses can sometimes relate to CAH and that major physical stressors (including surgery) can coincide with serious adrenal instability, though this is one case and does not predict what will happen for others.